Format

Send to

Choose Destination
Science. 2015 Nov 27;350(6264):1084-9. doi: 10.1126/science.aac4255. Epub 2015 Nov 5.

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.

Author information

1
Department of Pathology, University of Chicago, Chicago, IL 60637, USA.
2
Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
3
Section of Genetic Medicine, University of Chicago, Chicago, IL 60637, USA.
4
Department of Pathology, University of Chicago, Chicago, IL 60637, USA. Department of Medicine, University of Chicago, Chicago, IL 60637, USA. tgajewsk@medicine.bsd.uchicago.edu.

Abstract

T cell infiltration of solid tumors is associated with favorable patient outcomes, yet the mechanisms underlying variable immune responses between individuals are not well understood. One possible modulator could be the intestinal microbiota. We compared melanoma growth in mice harboring distinct commensal microbiota and observed differences in spontaneous antitumor immunity, which were eliminated upon cohousing or after fecal transfer. Sequencing of the 16S ribosomal RNA identified Bifidobacterium as associated with the antitumor effects. Oral administration of Bifidobacterium alone improved tumor control to the same degree as programmed cell death protein 1 ligand 1 (PD-L1)-specific antibody therapy (checkpoint blockade), and combination treatment nearly abolished tumor outgrowth. Augmented dendritic cell function leading to enhanced CD8(+) T cell priming and accumulation in the tumor microenvironment mediated the effect. Our data suggest that manipulating the microbiota may modulate cancer immunotherapy.

PMID:
26541606
PMCID:
PMC4873287
DOI:
10.1126/science.aac4255
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center